Sustained transduction of ocular cells with a bovine immunodeficiency viral vector

Kyoichi Takahashi, Tianci Luo, Yoshitsugu Saishin, Yumiko Saishin, Jennifer Sung, Sean Hackett, R. K. Brazzell, Michael Kaleko, Peter A Campochiaro

Research output: Contribution to journalArticle

Abstract

Human immunodeficiency viral (HIV) vectors mediate long-term transduction of many types of nondividing cells in vivo. Bovine immunodeficiency virus (BIV) is a lentivirus that shares many characteristics with HIV, but does not cause human disease. In this study, we investigated the potential of BIV vectors for ocular gene therapy. An enhanced green fluorescent protein (eGFP)-encoding reporter gene was packaged in recombinant BIV vector (BIV.eGFP). Adult C57BL/6 mice were given an intravitreous (5 × 104 or 5 × 105 transducing units |TU|) or subretinal (5 × 105 TU) injection of BIV.eGFP and then GFP expression was assessed at several time points. In vivo examinations of mice showed that subretinal injection of BIV.eGFP resulted in strong expression of GFP from the first examination at 1 week through the final examination at 20 weeks. Only a few mice that received intravitreous injection of BIV.eGFP showed GFP expression by ocular examinations until 11-12 weeks, when most showed small areas of expression. Postmortem examinations showed prominent GFP expression in retinal pigmented epithelial (RPE) cells throughout the region of subretinal injection of vector, although occasional negatively staining RPE cells were scattered among the much more numerous, brilliantly staining cells. Ciliary epithelial cells frequently expressed GFP, as did occasional Müller cells and rarely other retinal cells. The expression was stable from the first time point (2 weeks) to the last (20 weeks). Postmortem examination of eyes given an intravitreous injection of BIV.eGFP showed transduction of cells in the corneal endothelium and a few scattered retinal cells. There was no evidence of inflammation or toxicity in any eyes. These data show that BIV vectors mediate rapid and sustained transduction of RPE cells, suggesting that they may be useful for ocular gene therapy targeting RPE cells.

Original languageEnglish (US)
Pages (from-to)1305-1316
Number of pages12
JournalHuman Gene Therapy
Volume13
Issue number11
DOIs
StatePublished - 2002

Fingerprint

Bovine Immunodeficiency Virus
Epithelial Cells
Injections
Genetic Therapy
Autopsy
Staining and Labeling
Corneal Endothelium
Lentivirus
Gene Targeting
Inbred C57BL Mouse
Reporter Genes
enhanced green fluorescent protein

ASJC Scopus subject areas

  • Genetics

Cite this

Sustained transduction of ocular cells with a bovine immunodeficiency viral vector. / Takahashi, Kyoichi; Luo, Tianci; Saishin, Yoshitsugu; Saishin, Yumiko; Sung, Jennifer; Hackett, Sean; Brazzell, R. K.; Kaleko, Michael; Campochiaro, Peter A.

In: Human Gene Therapy, Vol. 13, No. 11, 2002, p. 1305-1316.

Research output: Contribution to journalArticle

Takahashi, K, Luo, T, Saishin, Y, Saishin, Y, Sung, J, Hackett, S, Brazzell, RK, Kaleko, M & Campochiaro, PA 2002, 'Sustained transduction of ocular cells with a bovine immunodeficiency viral vector', Human Gene Therapy, vol. 13, no. 11, pp. 1305-1316. https://doi.org/10.1089/104303402760128531
Takahashi, Kyoichi ; Luo, Tianci ; Saishin, Yoshitsugu ; Saishin, Yumiko ; Sung, Jennifer ; Hackett, Sean ; Brazzell, R. K. ; Kaleko, Michael ; Campochiaro, Peter A. / Sustained transduction of ocular cells with a bovine immunodeficiency viral vector. In: Human Gene Therapy. 2002 ; Vol. 13, No. 11. pp. 1305-1316.
@article{0c4a8d4be4ac4aee84762b08bd13308f,
title = "Sustained transduction of ocular cells with a bovine immunodeficiency viral vector",
abstract = "Human immunodeficiency viral (HIV) vectors mediate long-term transduction of many types of nondividing cells in vivo. Bovine immunodeficiency virus (BIV) is a lentivirus that shares many characteristics with HIV, but does not cause human disease. In this study, we investigated the potential of BIV vectors for ocular gene therapy. An enhanced green fluorescent protein (eGFP)-encoding reporter gene was packaged in recombinant BIV vector (BIV.eGFP). Adult C57BL/6 mice were given an intravitreous (5 × 104 or 5 × 105 transducing units |TU|) or subretinal (5 × 105 TU) injection of BIV.eGFP and then GFP expression was assessed at several time points. In vivo examinations of mice showed that subretinal injection of BIV.eGFP resulted in strong expression of GFP from the first examination at 1 week through the final examination at 20 weeks. Only a few mice that received intravitreous injection of BIV.eGFP showed GFP expression by ocular examinations until 11-12 weeks, when most showed small areas of expression. Postmortem examinations showed prominent GFP expression in retinal pigmented epithelial (RPE) cells throughout the region of subretinal injection of vector, although occasional negatively staining RPE cells were scattered among the much more numerous, brilliantly staining cells. Ciliary epithelial cells frequently expressed GFP, as did occasional M{\"u}ller cells and rarely other retinal cells. The expression was stable from the first time point (2 weeks) to the last (20 weeks). Postmortem examination of eyes given an intravitreous injection of BIV.eGFP showed transduction of cells in the corneal endothelium and a few scattered retinal cells. There was no evidence of inflammation or toxicity in any eyes. These data show that BIV vectors mediate rapid and sustained transduction of RPE cells, suggesting that they may be useful for ocular gene therapy targeting RPE cells.",
author = "Kyoichi Takahashi and Tianci Luo and Yoshitsugu Saishin and Yumiko Saishin and Jennifer Sung and Sean Hackett and Brazzell, {R. K.} and Michael Kaleko and Campochiaro, {Peter A}",
year = "2002",
doi = "10.1089/104303402760128531",
language = "English (US)",
volume = "13",
pages = "1305--1316",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "11",

}

TY - JOUR

T1 - Sustained transduction of ocular cells with a bovine immunodeficiency viral vector

AU - Takahashi, Kyoichi

AU - Luo, Tianci

AU - Saishin, Yoshitsugu

AU - Saishin, Yumiko

AU - Sung, Jennifer

AU - Hackett, Sean

AU - Brazzell, R. K.

AU - Kaleko, Michael

AU - Campochiaro, Peter A

PY - 2002

Y1 - 2002

N2 - Human immunodeficiency viral (HIV) vectors mediate long-term transduction of many types of nondividing cells in vivo. Bovine immunodeficiency virus (BIV) is a lentivirus that shares many characteristics with HIV, but does not cause human disease. In this study, we investigated the potential of BIV vectors for ocular gene therapy. An enhanced green fluorescent protein (eGFP)-encoding reporter gene was packaged in recombinant BIV vector (BIV.eGFP). Adult C57BL/6 mice were given an intravitreous (5 × 104 or 5 × 105 transducing units |TU|) or subretinal (5 × 105 TU) injection of BIV.eGFP and then GFP expression was assessed at several time points. In vivo examinations of mice showed that subretinal injection of BIV.eGFP resulted in strong expression of GFP from the first examination at 1 week through the final examination at 20 weeks. Only a few mice that received intravitreous injection of BIV.eGFP showed GFP expression by ocular examinations until 11-12 weeks, when most showed small areas of expression. Postmortem examinations showed prominent GFP expression in retinal pigmented epithelial (RPE) cells throughout the region of subretinal injection of vector, although occasional negatively staining RPE cells were scattered among the much more numerous, brilliantly staining cells. Ciliary epithelial cells frequently expressed GFP, as did occasional Müller cells and rarely other retinal cells. The expression was stable from the first time point (2 weeks) to the last (20 weeks). Postmortem examination of eyes given an intravitreous injection of BIV.eGFP showed transduction of cells in the corneal endothelium and a few scattered retinal cells. There was no evidence of inflammation or toxicity in any eyes. These data show that BIV vectors mediate rapid and sustained transduction of RPE cells, suggesting that they may be useful for ocular gene therapy targeting RPE cells.

AB - Human immunodeficiency viral (HIV) vectors mediate long-term transduction of many types of nondividing cells in vivo. Bovine immunodeficiency virus (BIV) is a lentivirus that shares many characteristics with HIV, but does not cause human disease. In this study, we investigated the potential of BIV vectors for ocular gene therapy. An enhanced green fluorescent protein (eGFP)-encoding reporter gene was packaged in recombinant BIV vector (BIV.eGFP). Adult C57BL/6 mice were given an intravitreous (5 × 104 or 5 × 105 transducing units |TU|) or subretinal (5 × 105 TU) injection of BIV.eGFP and then GFP expression was assessed at several time points. In vivo examinations of mice showed that subretinal injection of BIV.eGFP resulted in strong expression of GFP from the first examination at 1 week through the final examination at 20 weeks. Only a few mice that received intravitreous injection of BIV.eGFP showed GFP expression by ocular examinations until 11-12 weeks, when most showed small areas of expression. Postmortem examinations showed prominent GFP expression in retinal pigmented epithelial (RPE) cells throughout the region of subretinal injection of vector, although occasional negatively staining RPE cells were scattered among the much more numerous, brilliantly staining cells. Ciliary epithelial cells frequently expressed GFP, as did occasional Müller cells and rarely other retinal cells. The expression was stable from the first time point (2 weeks) to the last (20 weeks). Postmortem examination of eyes given an intravitreous injection of BIV.eGFP showed transduction of cells in the corneal endothelium and a few scattered retinal cells. There was no evidence of inflammation or toxicity in any eyes. These data show that BIV vectors mediate rapid and sustained transduction of RPE cells, suggesting that they may be useful for ocular gene therapy targeting RPE cells.

UR - http://www.scopus.com/inward/record.url?scp=0036376655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036376655&partnerID=8YFLogxK

U2 - 10.1089/104303402760128531

DO - 10.1089/104303402760128531

M3 - Article

VL - 13

SP - 1305

EP - 1316

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 11

ER -